Integrative Analysis to Identify Race-Associated Metabolite Biomarkers for Hepatocellular Carcinoma

Compared to European-Americans (EAs), the incidence of hepatocellular carcinoma (HCC) is higher in African-Americans (AAs) and is associated with more advanced tumor stage at diagnosis and lower survival rates. The increasing burden makes discovery of novel diagnostic, prognostic, and therapeutic bi...

Full description

Saved in:
Bibliographic Details
Main Authors: Chen, Yifan, Barefoot, Megan E., Varghese, Rency S., Wang, Kuijun, Di Poto, Cristina, Ressom, Habtom W.
Format: Conference Proceeding
Language:English
Subjects:
hepatocellular carcinoma
metabolomics
multi-omics
racial disparity
transcriptomics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Compared to European-Americans (EAs), the incidence of hepatocellular carcinoma (HCC) is higher in African-Americans (AAs) and is associated with more advanced tumor stage at diagnosis and lower survival rates. The increasing burden makes discovery of novel diagnostic, prognostic, and therapeutic biomarkers distinguishing HCC from underlying cirrhosis a significant focus. In this study, we analyzed tissue and serum samples from 40 HCC cases and 25 patients with liver cirrhosis to identify candidate biomarkers that distinguish HCC from cirrhotic patients in a race specific manner. Through integrative analysis of transcriptomic and metabolomic data, we investigated candidate metabolite biomarkers that are specific to AAs and EAs. The results from this demonstrate the utility of integrating transcriptomic and metabolomic data to prioritize clinically and biologically relevant metabolite biomarkers that can increase understanding of molecular mechanisms driving HCC in different racial groups.
ISSN:2375-7477
1558-4615
2694-0604
DOI:10.1109/EMBC44109.2020.9175697